Trump praises infertility product awarded FDA ‘voucher’
US President Donald Trump has welcomed the US Food and Drug Administration (FDA) awarding a ‘voucher’ to infertility product Pergoveris as part of an unprecedented new scheme.
Pergoveris was one of nine recipients of FDA vouchers handed out under the new Commissioner’s National Priority Voucher (CNPV) pilot programme, launched in July. The vouchers offer prescription drug and biological product developers an opportunity to reduce the drug and biological product application or efficacy supplement (ES) of their product. As part of the scheme, review times will go from 10-12 months to just one or two.
According to the FDA, each recipient has a product with significant potential to address a major national priority, such as meeting a large unmet medical need, addressing a public health crisis, boosting domestic manufacturing, or increasing medication affordability.
Commenting on a voucher being awarded to Pergoveris, Trump said: “This drug would directly compete against a much more expensive option that currently has a monopoly in the American market, and this will bring down costs very significantly.”
Other recipients of the vouchers include Teplizumab for Type 1 diabetes, DB-OTO for deafness and cytisinicline for nicotine vaping addiction.
Voucher recipients will receive a decision within one or two months following filing of a complete application for a drug or biologic. Sponsors will receive enhanced communications with review staff throughout the development process prior to their final submission and during the review period. If necessary, FDA scientists reserve the right to extend the review time if an application is incomplete, there are manufacturing violations, or as they otherwise deem appropriate.
“One of our core goals is to deliver more cures and meaningful treatments — especially ones that have an outsized impact on our most pressing national priorities,” said FDA Commissioner Marty Makary.
“We must modernise the review process and try new approaches to meet the needs of the American people.”
Bruno Quinney, Content Team, DDW
